Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $174 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $792 | $993 | $1,062 |
| Gross Profit | $0 | -$792 | -$993 | -$889 |
| % Margin | – | – | – | -511.7% |
| R&D Expenses | $720,973 | $0 | $0 | $1,062 |
| G&A Expenses | $553,299 | $652 | $464 | $563 |
| SG&A Expenses | $553,299 | $652 | $464 | $563 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$87 | -$129 | -$1,062 |
| Operating Expenses | $1,274,272 | $565 | $334 | $563 |
| Operating Income | -$1,274,272 | -$1,357 | -$1,328 | -$1,451 |
| % Margin | – | – | – | -835.7% |
| Other Income/Exp. Net | $20,194 | $29 | $21 | $10 |
| Pre-Tax Income | -$1,254,078 | -$1,327 | -$1,307 | -$1,442 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,254,078 | -$1,327 | -$1,307 | -$1,442 |
| % Margin | – | – | – | -830.1% |
| EPS | -0.28 | -0.31 | -0.64 | -1.37 |
| % Growth | 9.7% | 51.6% | 53.3% | – |
| EPS Diluted | -0.28 | -0.31 | -0.64 | -1.37 |
| Weighted Avg Shares Out | 4,549 | 4,305 | 1,048 | 1,048 |
| Weighted Avg Shares Out Dil | 4,549 | 4,305 | 1,048 | 1,048 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $29 | $21 | $10 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,164 | $1 | $1 | $1 |
| EBITDA | -$1,251,914 | -$1,356 | -$1,306 | -$1,441 |
| % Margin | – | – | – | -829.7% |